Search
MacroGenics Inc
MGNXAdd to Watchlist
3.690USD
-0.090-2.38%
Close 07-31 16:00（ET）Quotes delayed by 15 min
234.55MMarket Cap
LossP/E TTM
More Details of MacroGenics Inc Company
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
MacroGenics Inc Info
Ticker SymbolMGNX
Company nameMacroGenics Inc
IPO dateOct 10, 2013
CEORisser (Eric)
Number of employees341
Security typeOrdinary Share
Fiscal year-endOct 10
Address9704 Medical Center Drive
CityROCKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20850
Phone13012515172
Websitehttps://www.macrogenics.com/
Ticker SymbolMGNX
IPO dateOct 10, 2013
CEORisser (Eric)
Company Executives of MacroGenics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
206.04K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
114.75K
+3.27%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
47.82K
+7.84%
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
38.54K
+44.47%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
14.75K
+25.42%
Dr. Ezio Bonvini, M.D.
Dr. Ezio Bonvini, M.D.
Senior Vice President - Research, Chief Scientific Officer
Senior Vice President - Research, Chief Scientific Officer
--
--
Dr. David C. (Dave) Stump, M.D.
Dr. David C. (Dave) Stump, M.D.
Independent Director
Independent Director
--
--
Mr. Eric Risser
Mr. Eric Risser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Karen Jean Ferrante, M.D.
Dr. Karen Jean Ferrante, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
206.04K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
114.75K
+3.27%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
47.82K
+7.84%
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
38.54K
+44.47%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
14.75K
+25.42%
FAQs
Who are the top five shareholders of MacroGenics Inc?
The top five shareholders of MacroGenics Inc are: Mr. James Karrels
How many institutions hold shares of MacroGenics Inc (MGNX)?
As of 2026Q1, 326 institutions hold shares of MacroGenics Inc, with a combined market value of approximately 43.66M, accounting for 68.70% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -27380481.00.